Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN8282,120,86
Msft-0,67
Nokia4,0014,0480,20
IBM1,87
Mercedes-Benz Group AG50,8550,87-1,34
PFE0,04
23.09.2025 1:16:51
Indexy online
AD Index online
select
AD Index online
 

  • 22.09.2025
Abbott Labs (ABT.DE, Xetra)
Závěr k 22.9.2025 Změna (%) Změna (EUR) Objem obchodů (EUR)
116,04 0,57 0,66 71 122
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 23.09.2025
Popis společnosti
Obecné informace
Název společnostiAbbott Laboratories
TickerABT
Kmenové akcie:Ordinary Shares
RICABT
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky30.06.2025
Počet zaměstnanců k 31.12.2024 114 000
Akcie v oběhu k 30.06.20251 740 459 014
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice100 Abbott Park Road, Abbot Park
MěstoABBOTT PARK
PSČ60064-3500
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 246 676 100

Business Summary: Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Abbott Laboratories revenues increased 6% to $21.5B. Net income increased 23% to $3.1B. Revenues reflect Medical Devices segment increase of 12% to $9.92B, Nutritionals Products segment increase of 3% to $4.36B, Established Pharmaceutical Products segment increase of 5% to $2.64B, United States segment increase of 9% to $8.44B, All other Countries segment increase of 4% to $13.06B.
Odvětvová klasifikace
TRBC2012Medical Equipment, Supplies & Distribution (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICSIn-Vitro Diagnostic Substance Manufacturing
NAICSPharmaceutical Preparation Manufacturing
NAICSSurgical and Medical Instrument Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Electromedical Apparatus Mfg
NAICS2007Medicinal & Botanical Mfg
NAICS2007In-Vitro Diagnostic Substance Mfg
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Surgical & Medical Instrument Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
NAICS1997Medicinal and Botanical Manufacturing
NAICS1997InVitro Diagnostic Substance Manufacturing
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Surgical and Medical Instrument Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICElectromedical Equipment
SICMedicinals And Botanicals
SICDiagnostic Substances
SICPharmaceutical Preparations
SICSurgical And Medical Instruments
SICCommercial Physical Research



  • Poslední aktualizace: 23.09.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive Officer of the Company and the BankDominic Ng6624.08.201801.01.1992
Chief Financial Officer, Executive Vice PresidentChristopher Del Moral-Niles5402.10.202302.10.2023
Chief Operating Officer, Executive Vice PresidentParker Shi5501.12.202101.12.2021
Chief Human Resources Officer, Executive Vice PresidentGary Teo5201.01.2015
Executive Vice President, Chief Risk OfficerIrene Oh4702.10.202326.01.2010
Executive Vice President, General Counsel, Corporate SecretaryLisa Kim6001.01.2020
Executive Vice President and Head of Global BankingDeborah Leerhsen45
Vice President, Chief Corporate Officer of the Company and the BankDouglas Krause6801.01.1996